Oncolytic Efficacy of a Recombinant Vaccinia Virus Strain Expressing Bacterial Flagellin in Solid Tumor Models.
IVIS
LIVP
cytokine analysis
flagellin
vaccinia virus
virotherapy
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
24 03 2023
24 03 2023
Historique:
received:
15
02
2023
revised:
17
03
2023
accepted:
22
03
2023
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Oncolytic viral therapy is a promising novel approach to cancer treatment. Oncolytic viruses cause tumor regression through direct cytolysis on the one hand and recruiting and activating immune cells on the other. In this study, to enhance the antitumor efficacy of the thymidine kinase-deficient vaccinia virus (VV, Lister strain), recombinant variants encoding bacterial flagellin (subunit B) of
Identifiants
pubmed: 37112810
pii: v15040828
doi: 10.3390/v15040828
pmc: PMC10142208
pii:
doi:
Substances chimiques
Flagellin
12777-81-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Treat Rev. 2012 Nov;38(7):904-10
pubmed: 22651903
Gastroenterology. 2008 Aug;135(2):518-28
pubmed: 18538140
Lab Anim (NY). 2013 Jun;42(6):217-24
pubmed: 23689461
J Transl Med. 2011 Sep 27;9:164
pubmed: 21951588
Cancer Gene Ther. 2002 Dec;9(12):1001-12
pubmed: 12522439
Mol Ther. 2017 May 3;25(5):1107-1116
pubmed: 28392162
J Exp Clin Cancer Res. 2015 Feb 19;34:19
pubmed: 25887490
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2223-8
pubmed: 26858439
J Interferon Cytokine Res. 2019 Jan;39(1):6-21
pubmed: 29889594
Front Immunol. 2017 Oct 23;8:1390
pubmed: 29109732
Immunol Cell Biol. 2015 Jan;93(1):86-98
pubmed: 25223833
J Biol Chem. 2010 Feb 26;285(9):6477-88
pubmed: 20038581
Mol Ther. 2012 Apr;20(4):749-58
pubmed: 22186794
Curr Protoc Protein Sci. 2017 Aug 1;89:5.12.1-5.12.18
pubmed: 28762495
Methods Mol Biol. 2014;1180:31-43
pubmed: 25015141
J Exp Med. 2006 Apr 17;203(4):1093-104
pubmed: 16606669
Immunol Res. 2011 Aug;50(2-3):286-93
pubmed: 21717084
Clin Exp Metastasis. 2015 Dec;32(8):847-56
pubmed: 26385103
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Nature. 2001 Apr 26;410(6832):1099-103
pubmed: 11323673
Curr Opin Mol Ther. 2008 Aug;10(4):387-92
pubmed: 18683104
Hum Gene Ther. 2015 Mar;26(3):134-44
pubmed: 25557131
Mol Ther. 2011 Oct;19(10):1913-22
pubmed: 21772252
Future Oncol. 2010 Jun;6(6):941-9
pubmed: 20528232
Cancer Treat Rev. 2018 Feb;63:40-47
pubmed: 29207310
Surgery. 2007 Apr;141(4):520-9
pubmed: 17383529
J Innate Immun. 2014;6(1):47-57
pubmed: 23816851
Br J Cancer. 2022 Jun;126(10):1470-1480
pubmed: 35314795
Gene Ther. 2008 May;15(10):753-8
pubmed: 18356814
Methods Mol Biol. 1998;79:179-83
pubmed: 9463833
J Immunother Cancer. 2018 Dec 27;6(1):157
pubmed: 30587233
Methods Enzymol. 2019;629:151-176
pubmed: 31727238
J Biol Chem. 1994 May 13;269(19):13836-42
pubmed: 8188661
Sci Rep. 2019 May 27;9(1):7903
pubmed: 31133714
Genome Announc. 2016 May 12;4(3):
pubmed: 27174282
Gene Ther. 2015 Jun;22(6):476-84
pubmed: 25876464
Methods Mol Biol. 2004;269:31-40
pubmed: 15114005
Nat Immunol. 2006 Jun;7(6):569-75
pubmed: 16648853
Cancer Gene Ther. 1999 Sep-Oct;6(5):409-22
pubmed: 10505851
Vaccine. 2013 Aug 20;31(37):3879-87
pubmed: 23831323
Cell Prolif. 2018 Aug;51(4):e12441
pubmed: 29484738
Stem Cells Dev. 2022 Jan;31(1-2):9-17
pubmed: 34847755
World J Virol. 2016 May 12;5(2):85-6
pubmed: 27175354
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8
pubmed: 8876137
Oncotarget. 2014 Nov 30;5(22):11269-82
pubmed: 25358248
J Med Toxicol. 2022 Jan;18(1):43-55
pubmed: 33821435